219 related articles for article (PubMed ID: 30451116)
21. Evaluation of the purified fraction of Wilbrandia (c.f.) verticillata for antitumour activity.
Rao VS; Almeida FR; Moraes AP; Silva JV; Nascimento SC; Moraes MO
Mem Inst Oswaldo Cruz; 1991; 86 Suppl 2():43-5. PubMed ID: 1842011
[TBL] [Abstract][Full Text] [Related]
22. Cytotoxic effects of natural and semisynthetic cucurbitacins on lung cancer cell line A549.
Silva IT; Geller FC; Persich L; Dudek SE; Lang KL; Caro MS; Durán FJ; Schenkel EP; Ludwig S; Simões CM
Invest New Drugs; 2016 Apr; 34(2):139-48. PubMed ID: 26780083
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological studies of c(RGDyK) conjugates of cucurbitacins.
Chatzisideri T; Dalezis P; Leonidis G; Bousis S; Trafalis D; Bianchini F; Sarli V
Future Med Chem; 2021 May; 13(10):877-895. PubMed ID: 33858195
[TBL] [Abstract][Full Text] [Related]
24. Combretastatin-based compounds with therapeutic characteristics: a patent review.
Nainwal LM; Alam MM; Shaquiquzzaman M; Marella A; Kamal A
Expert Opin Ther Pat; 2019 Sep; 29(9):703-731. PubMed ID: 31369715
[No Abstract] [Full Text] [Related]
25. Recent Advances in the Application of Cucurbitacins as Anticancer Agents.
Zieniuk B; Pawełkowicz M
Metabolites; 2023 Oct; 13(10):. PubMed ID: 37887406
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological activity of new class of dioxygenated anticancer agents.
Pujol MD; Romero M; Sánchez I
Curr Med Chem Anticancer Agents; 2005 May; 5(3):215-37. PubMed ID: 15992351
[TBL] [Abstract][Full Text] [Related]
27. Ellagic acid derivatives and cytotoxic cucurbitacins from Elaeocarpus mastersii.
Ito A; Chai HB; Lee D; Kardono LB; Riswan S; Farnsworth NR; Cordell GA; Pezzuto JM; Kinghorn AD
Phytochemistry; 2002 Sep; 61(2):171-4. PubMed ID: 12169311
[TBL] [Abstract][Full Text] [Related]
28. Cytotoxic cucurbitane triterpenoids isolated from the rhizomes of Hemsleya amabilis.
Chen XB; Chen GY; Liu JH; Lei M; Meng YH; Guo DA; Liu X; Hu LH
Fitoterapia; 2014 Apr; 94():88-93. PubMed ID: 24462673
[TBL] [Abstract][Full Text] [Related]
29. Coumarin-based drugs: a patent review (2008 -- present).
Kontogiorgis C; Detsi A; Hadjipavlou-Litina D
Expert Opin Ther Pat; 2012 Apr; 22(4):437-54. PubMed ID: 22475457
[TBL] [Abstract][Full Text] [Related]
30. Cucurbitacin E, An Experimental Lead Triterpenoid with Anticancer, Immunomodulatory and Novel Effects Against Degenerative Diseases. A Mini-Review.
Attard E; Martinoli MG
Curr Top Med Chem; 2015; 15(17):1708-13. PubMed ID: 25915611
[TBL] [Abstract][Full Text] [Related]
31. Structures of cayaponosides A, B, C and D, glucosides of new nor-cucurbitacins in the roots of Cayaponia tayuya.
Himeno E; Nagao T; Honda J; Okabe H; Irino N; Nakasumi T
Chem Pharm Bull (Tokyo); 1992 Oct; 40(10):2885-7. PubMed ID: 1464123
[No Abstract] [Full Text] [Related]
32. Plant anticancer agents. XXX: Cucurbitacins from Ipomopsis aggregata (Polemoniaceae).
Arisawa M; Pezzuto JM; Kinghorn AD; Cordell GA; Farnsworth NR
J Pharm Sci; 1984 Mar; 73(3):411-3. PubMed ID: 6546946
[TBL] [Abstract][Full Text] [Related]
33. Natural Product Triterpenoids and Their Semi-Synthetic Derivatives with Potential Anticancer Activity.
Ren Y; Kinghorn AD
Planta Med; 2019 Aug; 85(11-12):802-814. PubMed ID: 30658371
[TBL] [Abstract][Full Text] [Related]
34. Actin-aggregating cucurbitacins from Physocarpus capitatus.
Maloney KN; Fujita M; Eggert US; Schroeder FC; Field CM; Mitchison TJ; Clardy J
J Nat Prod; 2008 Nov; 71(11):1927-9. PubMed ID: 18959442
[TBL] [Abstract][Full Text] [Related]
35. A Link Between Chemical Structure and Biological Activity in Triterpenoids.
Zang L; Xu H; Huang C; Wang C; Wang R; Chen Y; Wang L; Wang H
Recent Pat Anticancer Drug Discov; 2022; 17(2):145-161. PubMed ID: 33982656
[TBL] [Abstract][Full Text] [Related]
36. [Cucurbitacins in the treatment of hepatitis and primary liver cancer. Current status of pharmacological and clinical research].
Ren FB; Hong M
Zhong Xi Yi Jie He Za Zhi; 1986 Oct; 6(10):633-5. PubMed ID: 2949871
[No Abstract] [Full Text] [Related]
37. Multivariate SAR and QSAR of cucurbitacin derivatives as cytotoxic compounds in a human lung adenocarcinoma cell line.
Lang KL; Silva IT; Machado VR; Zimmermann LA; Caro MS; Simões CM; Schenkel EP; Durán FJ; Bernardes LS; de Melo EB
J Mol Graph Model; 2014 Mar; 48():70-9. PubMed ID: 24378396
[TBL] [Abstract][Full Text] [Related]
38. Polymeric micelles for the solubilization and delivery of STAT3 inhibitor cucurbitacins in solid tumors.
Molavi O; Ma Z; Mahmud A; Alshamsan A; Samuel J; Lai R; Kwon GS; Lavasanifar A
Int J Pharm; 2008 Jan; 347(1-2):118-27. PubMed ID: 17681440
[TBL] [Abstract][Full Text] [Related]
39. Lipid-Lowering Activities of Cucurbitacins Isolated from
Zhang X; Li H; Wang W; Chen T; Xuan L
J Nat Prod; 2020 Dec; 83(12):3536-3544. PubMed ID: 33269591
[TBL] [Abstract][Full Text] [Related]
40. A fruitful decade from 2005 to 2014 for anthraquinone patents.
Hussain H; Al-Harrasi A; Al-Rawahi A; Green IR; Csuk R; Ahmed I; Shah A; Abbas G; Rehman NU; Ullah R
Expert Opin Ther Pat; 2015; 25(9):1053-64. PubMed ID: 26036306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
